参考文献/References:
[1] Li X,Sun X,Huang Y,et al. Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease[J]. Clin Rheumatol,2019,38(12):3619-3626.
[2] Oliveira RP,Ribeiro R,Melo L,et al. Connective tissue disease-associated interstitial lung disease[J]. Pulmonology,2020,S2531-0437(20)30004-0.
[3] Raina A,Benza RL,Farber HW. Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series[J]. Pulm Circ,2017,7(3):741-746.
[4] 汪汉. 结缔组织疾病相关肺动脉高压的比较[J].心血管病学进展,2017,38(6):700-703.
[5] 陈悦,陈超美,刘则渊,等. CiteSpace知识图谱的方法论功能[J]. 科学学研究,2015,33(2):242-253.
[6] Condliffe R,Kiely DG,Peacock AJ,et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era[J]. Am J Respir Crit Care Med,2009,179(2):151-157.
[7] Coghlan JG,Denton CP,Grünig E,et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study[J]. Ann Rheum Dis,2014,73(7) :1340-1349.
[8] Steen VD,Medsger TA. Changes in causes of death in systemic sclerosis,1972-2002[J]. Ann Rheum Dis,2007,66(7):940-944.
[9] Galiè N,Hoeper MM,Humbert M,et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)[J]. Eur Heart J,2009,30(20):2493-2537.
[10] Galiè N,Humbert M,Vachiery JL,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC),International Society for Heart and Lung Transplantation (ISHLT) [J]. Eur Heart J,2016,37(1):67-119.
[11] Chung L,Liu J,Parsons L,et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype[J]. Chest,2010,138(6):1383-1394.
[12] Humbert M,Yaici A,de Groote P,et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival[J]. Arthritis Rheum,2011,63(11):3522-3530.
[13] Galiè N,Denton CP,Dardi F,et al. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease[J]. Int J Cardiol,2017,235:67-72.
[14] Coghlan JG,Galiè N,Barbera JA,et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial[J]. Ann Rheum Dis,2017,76(7):1219-1227.
[15] Saggar R,Khanna D,Furst DE,et al. Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities[J]. Arthritis Rheum,2010,62(12):3741-3750.
[16] Price LC,Wort SJ,Perros F,et al. Inflammation in pulmonary arterial hypertension[J]. Chest,2012,141(1):210-221.
[17] Dib H,Tamby MC,Bussone G,et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma[J]. Eur Respir J,2012,39(6):1405-1414.
[18] Strange G,Playford D,Stewart S,et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort[J]. Heart,2012,98(24):1805-1811.
[19] Zhang R,Dai LZ,Xie WP,et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era[J]. Chest,2011,140(2):301-309.
[20] Zhang ZN,Jiang X,Zhang R,et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective,open-label,multicentre study[J]. Heart,2011,97(22):1876-1881.
[21] Hinchcliff M,Fischer A,Schiopu E,et al. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population[J]. J Rheumatol,2011,38(10):2172-2179.
[22] Thakkar V,Stevens WM,Prior D,et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study[J]. Arthritis Res Ther,2012,14(3):R143.
[23] Preston IR,Roberts KE,Miller DP,et al. Effect of Warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)[J]. Circulation,2015,132(25):2403-2411.
[24] Stamm A,Saxer S,Lichtblau M,et al. Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis[J]. Eur Respir J,2016,48(6):1658-1667.
相似文献/References:
[1]周力,李虹伟.结缔组织病并发冠状动脉性心脏病的危险因素[J].心血管病学进展,2015,(5):567.[doi:10.3969/j.issn.1004-3934.2015.05.011]
ZHOU Li,LI Hongwei.Risk Factors for Coronary Heart Disease in Connective Tissue Diseases[J].Advances in Cardiovascular Diseases,2015,(12):567.[doi:10.3969/j.issn.1004-3934.2015.05.011]
[2]徐学萍 汪汉 蔡琳.结缔组织病相关心脏瓣膜病[J].心血管病学进展,2019,(9):1267.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.021]
XU Xueping,WANG Han,CAI Lin.Connective Tissue Disease-associated Valvular Heart Disease[J].Advances in Cardiovascular Diseases,2019,(12):1267.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.021]
[3]杨子玄?刘圣?亢玉?张庆.新指标评估结缔组织病患者动脉僵硬度及其对左室舒张功能的影响[J].心血管病学进展,2022,(5):475.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.021]
YANG Zixuan,LIU Sheng,KANG Yu,et al.Arterial Stiffness Assessed by New Indices in Patients with Connective Tissue Disease and Their Association with Left Ventricular Diastolic Function[J].Advances in Cardiovascular Diseases,2022,(12):475.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.021]
[4]唐建辉 陈锋 汪汉.血清尿酸与结缔组织病[J].心血管病学进展,2022,(8):743.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.019]
TANG Jianhui,CHEN Feng,WANG Han?/html>.Serum Uric Acid and Connective Tissue Diseases[J].Advances in Cardiovascular Diseases,2022,(12):743.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.019]